Journal of Pharmacology and Experimental Therapeutics 1999-09-01

Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.

L M Shuba, Y Kasamaki, S E Jones, T Ogura, J R McCullough, T F McDonald

Index: J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999)

Full Text: HTML

Abstract

Terodiline was widely prescribed for urinary incontinence before reports of adverse cardiac effects that included bradycardia, QT lengthening, and ventricular tachyarrhythmia. The present study on guinea pig papillary muscles and ventricular myocytes was undertaken to gain insight into the cardioactive properties of the drug. Clinically relevant concentrations (<10 microM) of terodiline lengthened the action potential duration by up to 12%; higher concentrations shortened the duration in a concentration-dependent manner. The drug depressed maximal upstroke velocity in a use-dependent manner; the IC(50) value was near 150 microM in muscles driven at 1 Hz, 60 microM at 3 Hz, 38 microM at 5 Hz, and 3 microM at 1 Hz in muscles depolarized with 14 mM K(+). Submicromolar terodiline frequently had a small positive inotropic effect, whereas micromolar concentrations depressed force in a frequency-dependent manner. Voltage-clamp results on myocytes indicate that terodiline inhibits three membrane currents that govern repolarization: 1) E4031-sensitive, rapidly activating K(+) current with an IC(50) value near 0.7 microM as previously reported; 2) slowly activating, delayed-rectifier K(+) current with an IC(50) value of 26 microM; and 3) L-type Ca(2+) current with an IC(50) value of 12 microM. These findings are correlated with the changes in action potential configuration and developed tension and discussed in relation to the cardiotoxic effects of the drug.


Related Compounds

Related Articles:

Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.

1998-01-01

[Gen. Pharmacol. 30(1) , 137-42, (1998)]

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

2000-07-01

[Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000)]

Inhibition of cardiac inward-rectifier K+ current by terodiline.

1999-07-01

[Eur. J. Pharmacol. 370(3) , 319-27, (1999)]

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.

2001-01-01

[Xenobiotica 31(8-9) , 633-50, (2001)]

In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.

2006-11-01

[J. Cardiovasc. Pharmacol. 48(5) , 199-206, (2006)]

More Articles...